Tag Archives: Hepatitis C

‘Warehousing’ and the Future of HCV Treatment

The battle against hepatitis C (HCV) is a relatively new, and highly dynamic, one.  The viral disease was only discovered in the 1980’s and, according to WHO estimates, some 3% of the world’s population are now infected with HCV and there are more than 170 million chronic carriers. So what does the HCV treatment landscape look […]
Posted in healthcare, Strategy | Also tagged , | Leave a comment

How Gilead “Blew Out the Lights” With Sovaldi

While flipping through my emails recently, I froze before an image that appeared on my screen. An old Rx colleague had sent me a graph, mapping out the 2014 U.S. sales achieved by Gilead’s Hep C drug, Sovaldi. It was stunning. Take a look:
Posted in Marketing, pricing, Strategy | Also tagged , | 2 Comments

Pharmaceutical Care Management Association Releases Hep C Medicare Part D Impact Study

As the controversy over Sovaldi’s $84,000 per therapy cost continues to build, the Pharmaceutical Care Management Association has released a study on the impact of the new Hepatitis C drugs on the overall costs to the US Medicare Part D pharmaceutical program (http://www.pcmanet.org/images/stories/uploads/2014/partdpremiumstudymilliman.pdf)
Posted in healthcare, pricing | Also tagged , , , | Leave a comment

The Market Will Demand a Cheaper Alternative to Sovaldi

A new report from Frost & Sullivan forecasts “robust demand” for HCV antivirals, with several strong competitors “maneuvering aggressively” to narrow the market gap by introducing a treatment that can outdo Gilead’s Sovaldi.
Posted in healthcare, pricing, Strategy | Also tagged , , | Leave a comment

High Price of Gilead's Sovaldi Could Deter Early Hep C Treatment

Gilead Silences has cleaned up on their new $1,000 Hepatitis C pill Sovaldi (84,000 per treatment), hauling in a record-breaking $2.3 billion in its first full quarter on the market. The previous record (also a Hepatitis C drug Incivek from Vertex) came in with $1.56 billion, according to EP Vantage. And Sovaldi may well go […]
Posted in healthcare, pricing | Also tagged , | 1 Comment
  • Categories

  • Meta